Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus GENCEPT 10 11 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus GENCEPT 10 11 21.
ENOVID-E vs GENCEPT 10/11-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life is 24-30 hours; allows once-daily dosing; steady-state achieved in 5-7 days
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal (30-40% as unchanged drug and metabolites), biliary/fecal (50-60% as metabolites)
Category C
Category C
Oral Contraceptive
Oral Contraceptive